SCHEMBL18940545

SCHEMBL18940545

O=C(O)n1c(-c2cccnc2)cc2cc(Cl)ccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 3/20 0.52
KCNH2 Q12809 1/20 0.49
AOC3 Q16853 1/20 0.49
TBXAS1 P24557 1/20 0.43
KLK7 P49862 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
MAPK1 P28482 1/20 0.42
ATM Q13315 1/20 0.42
CYP19A1 P11511 1/20 0.41
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
F2 P00734 1/20 0.41
F12 P00748 1/20 0.41
MAPT P10636 1/20 0.41
KLK5 Q9Y337 1/20 0.41
CNR1 P21554 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18940539 0.85 CYP2A6 (0.47) KLK7NPC1RAB9ACYP11B1CYP11B2
SCHEMBL27830572 0.85 ACLY (0.47) ACLYCYP19A1CYP11B1CYP11B2F2
SCHEMBL16760261 0.83 TTK (0.51) ACLYKCNH2AOC3CYP3A4
SCHEMBL24115004 0.79 AOC3 (0.53) ACLYKCNH2AOC3TBXAS1NPC1
SCHEMBL22003806 0.75 HTT (0.50) ACLYKCNH2AOC3NPC1RAB9A
SCHEMBL16760207 0.75 ACLY (0.50) ACLYKCNH2AOC3NPC1RAB9A
SCHEMBL27810052 0.74 AOC3 (0.45) ACLYAOC3KDM4E
SCHEMBL27830512 0.72 KMO (0.39) ACLYKCNH2AOC3CYP11B1CYP11B2
SCHEMBL22003805 0.72 AOC3 (0.46) ACLYKCNH2AOC3TBXAS1NPC1
SCHEMBL28981319 0.71 ACLY (0.46) ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3074385-B1 PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS TAKEDA PHARMACEUTICALS CO (JP) 2021-12-22 EP disclosed
US-10562882-B2 Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-18 US disclosed
US-20170166553-A1 Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166553-A1 Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions GRIN2C, GRIN2A, PNMT ACLY 1915/4885KCNH2 341/4885AOC3 1713/4885
US-10562882-B2 Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions GRIN2C, GRIN2A, PNMT ACLY 1915/4885KCNH2 341/4885AOC3 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.